Serial No.: 09/762,926

Docket No.: BM45330

## In the Claims:

Claims 1-68 (Cancelled)

69. (Currently Amended): An isolated polypeptide comprising a member selected from the

group-consisting-of

(a) — an amino acid-sequence matching SEQ ID NO:4 and

(b) an immunogenic polypeptide comprising a fragment sequence of at least 15

amino acids that matches an identically aligned contiguous segment of SEQ-ID

NO:4,

wherein the isolated polypeptide, when administered to a subject in a suitable composition which

can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or

T-cell immune response to a polypeptide having the sequence of SEQ ID NO:4.

Claims 70-76 Cancelled

77. (Previously Added): The isolated polypeptide of claim 69, wherein the isolated

polypeptide consists of SEQ ID NO:4.

Claims 78-79 Cancelled

80. (Previously Added): A fusion protein comprising the isolated polypeptide of Claim 69.

Claims 81-91 (Cancelled)

92. (New): The isolated polypeptide of claim 69, wherein the isolated polypeptide is an

isolated, recombinant polypeptide.

93. (New): The isolated polypeptide of claim 77, wherein the isolated polypeptide is an

isolated, recombinant polypeptide.

4

Serial No.: 09/762,926 Docket No.: BM45330

94. (New): The fusion protein of claim 80, wherein the fusion protein is a recombinant protein.